Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Oncology

pharma-news-for-amgen-novo-nordisk-boehringer

Notizia - Recent Pharma, Healthcare and Biotech Happenings

FDA Approves LUMAKRAS with VECTIBIX for KRAS G12C-Mutated Colorectal Cancer; PYC Receives FDA Rare Pediatric Disease Designation for VP-001; Novo Nordisk Links High-Dose WEGOVY to Increased Weight Loss; FDA Rejects Atara’s EBVALLO Due to Manufacturing Issues; Boehringer Faces Phase III Schizophrenia Fail and Legal Challenges

Explore More...
pharma-news-for-agios-bridgebio-rigel

Agios’ PYRUKYND SNDA Accepted by FDA for Thalassemia; BridgeBio’s BBO-8520 Gets FDA Fast Track for KRASG12C-Mutated Lung Cancer; Nipocalimab Granted FDA Priority Review for Myasthenia Gravis; Rigel’s R289 Receives FDA Orphan Drug Designation for MDS; Rise Therapeutics Gets FDA IND Clearance for R-5780 in Cancer

bms-dominance-in-molecular-glue-landscape

Bristol Mayer Squibb — The Undisputed Leader in the Molecular Glue Arena

rise-of-molecular-glues

The Rise of Molecular Glues: Transforming Protein-Protein Interactions into Therapeutic Opportunities

pharma-news-for-chimerix-verastem-capricor

Chimerix Submits Dordaviprone NDA for Accelerated Approval in Recurrent H3 K27M-Mutant Diffuse Glioma to FDA; NMD Pharma’s NMD670 Receives FDA Orphan Drug Designation for Charcot-Marie-Tooth Disease; Verastem’s Avutometinib NDA Accepted for KRAS Mutant Ovarian Cancer; Capricor Submits BLA for Deramiocel in Duchenne Muscular Dystrophy; Axsome Completes Phase III Trial of AXS-05 for Alzheimer’s Agitation

pharma-news-for-precigen-bms-sapience

FDA Approves Opdivo Qvantig™ for Solid Tumors; Nuvation Bio’s Taletrectinib NDA Accepted for ROS1-Positive NSCLC; HKBU’s Aptamer for X-Linked Hypophosphatemia Gets FDA Orphan Designation; Sapience’s ST316 Receives FDA Orphan Status for FAP; Precigen Submits BLA for PRGN-2012 in RRP

pharma-news-for-neurocrine-checkpoint-maia

FDA Approves Neurocrine’s CRENESSITY for Congenital Adrenal Hyperplasia; Checkpoint’s UNLOXCYT Approved; MAIA’s THIO Gets Rare Pediatric Disease Designation; JEMPERLI  Receives Breakthrough Therapy for Rectal Cancer; Galderma’s NEMLUVIO Approved for Atopic Dermatitis.

bizengri-for-nrg1-cancer-patients

Merus’ BIZENGRI: The New Face of NRG1+ Cancer Treatment After FDA Approval

imfinzi-for-ls-sclc

AstraZeneca’s IMFINZI Archives Another Milestone — Becomes the First Immunotherapy for Limited-Stage Small-cell Lung Cancer

medtech-news-for-angiodynamics-zynex-cota

Stereotaxis and Shanghai MicroPort EP Medtech Co., Ltd. Receives Approval for Magbot Robotic Magnetic Navigation Ablation Catheter From China’s NMPA; AngioDynamics NanoKnife® System Approved by FDA for Prostate Tissue Treatment; Zynex Successfully Completes Laser Pulse Oximetry Clinical Trial; COTA, PreciseDx, and Baptist Health Validate AI-Powered PreciseBreast as Equivalent to Oncotype DX; Medtronic Introduces Percept™ RC Rechargeable Neurostimulator; Crown Aesthetics Raises the Bar with the Introduction of SkinPen® Precision Elite

pharma-news-for-abbvie-gsk-novartis

AbbVie Reveals Phase III TEMPO-2 Trial Positive Topline Results; FDA Accepts GSK’s NUCALA Submission in COPD; Novartis Boosts Huntington’s Disease Development Program with PTC518 In-Licensing; Chimerix to File for Accelerated FDA Approval of Dordaviprone for H3 K27M-Mutant Diffuse Glioma; MeiraGTx Receives FDA RMAT Designation for AAV2-hAQP1 in Grade 2/3 Radiation-Induced Xerostomia Treatment

potential-of-cdk4-6-inhibitors

How CDK4/6 Inhibitors Are Changing the Cancer Treatment Paradigm?

applications-of-biochips-in-healthcare

Biochips in Healthcare: 8 Groundbreaking Applications Shaping the Industry

pharma-news-for-applied-therapeutics-alnylam-rigel

FDA Grants Fast Track for Lin BioScience’s LBS-007; Alnylam’s AMVUTTRA sNDA Under Review; FDA Approves RAPIBLYK for Atrial Fibrillation; Applied Therapeutics Receives CRL for Govorestat in Galactosemia; R289 Gets Fast Track for Lower-Risk MDS.

EGFR-NSCLC Treatment Market Dynamics

Evaluating Key Advancements and Emerging Therapies in EGFR-Non Small Cell Lung Cancer Treatment Market

Novel Insights Into The Non-Small Cell Lung Cancer Market

Novel Mutation-Targeting Therapies in the Horizon to Relieve the Global Healthcare Burden NSCLC Poses

Novel Mutation-Targeting Therapies in the Horizon to Relieve the Global Healthcare Burden NSCLC Poses

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader